



Neves, K. B., Morris, H., Alves-Lopes, R., Muir, K. W., Moreton, F., Delles, C., Montezano, A. C. and Touyz, R. M. (2021) Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO/sGC/cGMP pathway. *Clinical Science*, 135(6), pp. 753-773.

(doi: [10.1042/CS20201412](https://doi.org/10.1042/CS20201412))

This is the Author Accepted Manuscript.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/236204/>

Deposited on: 9 March 2021

1 **Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves**
2 **ER and oxidative stress and blunting of NO/sGC/cGMP pathway**

3
4 *Karla B Neves, PhD¹; Hannah Morris, MSc¹; Rhéure Alves-Lopes, PhD¹; Keith W
5 Muir, MD, PhD²; Fiona Moreton, MD, PhD ²; Christian Delles, MD, PhD¹; Augusto C
6 Montezano, PhD¹; *Rhian M Touyz, MD, PhD¹.

7
8
9 ¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK;

10 ²Institute of Neuroscience & Psychology, University of Glasgow and Queen Elizabeth
11 University Hospital.

12
13 **Short title:** Peripheral arteriopathy and CADASIL

14 **Category of Manuscript:** Original Article

15
16
17
18 **To whom correspondence should be addressed:**

19 *Karla B Neves PhD and Rhian M Touyz MD, PhD

20 Institute of Cardiovascular and Medical Sciences,
21 University of Glasgow,

22 126 University Place, Glasgow, G12 8TA,

23 Glasgow, UK

24 Phone: + 44 (0)141 330 7775/7774,

25 Fax: + 44 (0)141 330 3360,

26 Email: Karla.Neves@glasgow.ac.uk; Rhian.Touyz@glasgow.ac.uk

27

28 **Abstract**

29 Notch3 mutations cause Cerebral Autosomal Dominant Arteriopathy with Subcortical
30 Infarcts and Leukoencephalopathy (CADASIL), which predisposes to stroke and
31 dementia. CADASIL is characterized by vascular dysfunction and granular osmiophilic
32 material (GOM) accumulation in cerebral small vessels. Systemic vessels may also
33 be impacted by Notch3 mutations. However vascular characteristics and
34 pathophysiological processes remain elusive. We investigated mechanisms
35 underlying the peripheral vasculopathy mediated by CADASIL-causing Notch3 gain-
36 of-function mutation. We studied: i) small arteries and vascular smooth muscle cells
37 (VSMC) from TgNotch3^{R169C} mice (CADASIL model), ii) VSMCs from peripheral
38 arteries from CADASIL patients, and iii) post-mortem brains from CADASIL individuals.
39 TgNotch3^{R169C} vessels exhibited GOM deposits, increased vasoreactivity and
40 impaired vasorelaxation. Hypercontractile responses were normalized by fasudil (Rho
41 kinase inhibitor) and 4-PBA (endoplasmic-reticulum (ER) stress inhibitor). Ca²⁺
42 transients and Ca²⁺ channel expression were increased in CADASIL VSMCs, with
43 increased expression of Rho GEFs and ER stress proteins. Vasorelaxation
44 mechanisms were impaired in CADASIL, evidenced by decreased eNOS
45 phosphorylation and reduced cGMP levels, with associated increased guanylate
46 cyclase (sGC) oxidation, decreased sGC activity and reduced levels of the vasodilator
47 H₂O₂. In VSMCs from CADASIL patients, sGC oxidation was increased and cGMP
48 levels decreased, effects normalized by fasudil and 4-PBA. Cerebral vessels in
49 CADASIL patients exhibited significant oxidative damage. In conclusion, peripheral
50 vascular dysfunction in CADASIL is associated with altered Ca²⁺ homeostasis,
51 oxidative stress and blunted eNOS/sGC/cGMP signaling, processes involving Rho
52 kinase and ER stress. We identify novel pathways underlying the peripheral

53 arteriopathy induced by Notch3 gain-of-function mutation, phenomena that may also
54 be important in cerebral vessels.

55

56 **Key words:** Notch3, small arteries, vascular signalling, oxidation, vascular dementia.

57

58 **Introduction**

59 Notch proteins are cell membrane receptors that play a crucial role in cell-to-cell
60 communication [1]. In mammals four Notch receptors and five ligands have been
61 identified and although they share the same primary structure, Notch receptors are
62 expressed in a cell-specific manner and mediate diverse cellular effects [2, 3]. Notch
63 signalling induces transcription of target genes that influence cell differentiation,
64 maturation, proliferation and apoptosis and is critically involved in the regulation of
65 vascular smooth muscle cell (VSMC) function [4, 5]. In the vasculature, of the Notch
66 receptor family, Notch3 is expressed predominantly in VSMCs, where it controls
67 maintenance of cell phenotype and growth [5, 6]. Abnormal Notch3 signalling has been
68 implicated in cardiovascular diseases associated with excessive VSMC proliferation
69 and vascular remodeling such as pulmonary arterial hypertension [4].

70 Mutations of Notch3 are responsible for the monogenic inherited cerebral
71 arteriopathy known as Cerebral Autosomal Dominant Arteriopathy with Subcortical
72 Infarctions and Leukoencephalopathy (CADASIL) that leads to premature stroke and
73 vascular dementia [7]. Progressive degeneration of VSMCs, accumulation of
74 abnormal protein (granular osmiophilic material (GOM)) around VSMCs, and
75 cerebrovascular dysfunction are characteristic features of CADASIL [7, 8]. In the brain,
76 these processes present as subcortical lacunes and white matter rarefaction due to

77 chronic ischaemia, and manifest clinically as premature stroke, mood and behaviour
78 disturbances, cognitive decline, migraines and dementia [9-11].

79 Investigations of the pathogenesis and molecular mechanisms of CADASIL
80 have been performed in large part using experimental models of CADASIL and
81 cultured patient-derived VSMCs and induced pluripotent stem cells [12-14]. We
82 recently demonstrated that isolated small peripheral arteries from CADASIL patients
83 exhibit vascular dysfunction and structural remodelling with associated VSMC
84 oxidative and endoplasmic reticulum (ER) stress and altered Rho kinase signalling
85 (12). Proteomic analysis in VSMCs from a CADASIL patient showed increased
86 expression of proteins involved in protein degradation/folding, cytoskeletal
87 organisation, contraction and cell stress [15].

88 Vascular remodeling in CADASIL mice is related to increased deposition of
89 extracellular matrix (ECM) proteins [14, 16, 17], VSMC proliferation and cellular
90 mitochondrial dysfunction [12, 18-20]. Studies in a CADASIL mouse model,
91 TgNotch3^{R169C} mice, demonstrated cerebrovascular dysfunction and thickening, with
92 associated increased deposition of extracellular matrix proteins, upregulation of
93 voltage-dependent potassium (Kv1) channels, blunted membrane depolarization and
94 reduced myogenic tone [14, 21].

95 Although the genetic cause of CADASIL is known and the clinical features of
96 CADASIL are well defined, understanding the molecular and cellular processes
97 underlying the vasculopathy induced by the Notch3 mutations still remain incompletely
98 understood. This is attributed to the wide genetic diversity of Notch3 mutations, but
99 also to the incomplete understanding of Notch3 function in blood vessels. Our previous
100 findings identified important interplay between vascular Notch3, ER stress and Rho
101 kinase, in part through Nox5-derived reactive oxygen species (ROS), in CADASIL

102 patients [12]. Here we have further interrogated molecular and cellular mechanisms
103 whereby a Notch3 gain-of-function mutation alters vascular function of peripheral small
104 arteries, using a mouse model harbouring one of more than 200 distinct Notch3
105 mutations already described as associated with CADASIL [22].

106

107 **Methods**

108 **Study approval**

109 Ethics approval for the use of human blood vessel samples was obtained from the
110 West of Scotland Research Ethics Service (WS/12/0294). Written informed consent
111 was obtained for all study participants in accordance with the Declaration of Helsinki.
112 Human brain samples were from biobanked tissue from NHSGGC Biorepository and
113 Pathology Service Tissue Resource. Ethical approval for use of surplus tissue from
114 diagnostic blocks was obtained (REC 16/WS/0207). Experiments were approved by
115 the University of Glasgow Animal Welfare and Ethics Review Board. All experimental
116 protocols on mice were performed in accordance with the United Kingdom Animals
117 Scientific Procedures Act 1986 (Licence No. 70/9021) and with ARRIVE Guidelines.
118 All animal studies were conducted in the Institute of Cardiovascular and Medical
119 Sciences at the University of Glasgow, UK.

120 **Subject recruitment**

121 Patients with genetically confirmed CADASIL were recruited from the Neurovascular
122 Genetics clinic, Queen Elizabeth University Hospital, Glasgow. Healthy controls were
123 volunteers at the hospital. Under local anaesthetic, all subjects underwent a gluteal
124 biopsy from which intact small arteries (<400 μm diameter) were dissected from
125 subcutaneous fat. VSMCs were isolated for primary cell culture, as previously

126 described [23, 24] and summarized below. Identical protocols were used for CADASIL
127 patients and control studies.

128 **Human brain samples from patients with CADASIL**

129 Human brain samples were from biobanked tissue from NHSGGC Biorepository and
130 Pathology Service Tissue Resource. At routine diagnostic autopsy, whole brains were
131 immersion fixed in 10% formal saline for a minimum of 2 weeks prior to dissection,
132 standardized anatomical sampling, tissue processing and embedding in paraffin as
133 previously described [25]. From diagnostic blocks, sections of 5 μ m were dissected.
134 Samples where blood vessels were visible were chosen. We studied four brains from
135 CADASIL patients and three brains from individuals who had died from various causes
136 (Supplemental Table 1).

137 **Mouse model of CADASIL**

138 The transgenic (Tg) mouse lines, TgNotch3^{WT} and TgNotch3^{R169C}, have been
139 previously characterized and described. Briefly, TgNotch3^{WT} and TgNotch3^{R169C} mice
140 (on an FVB background) express rat wild-type Notch3 and the CADASIL-causing
141 Notch3(R169C) mutant protein, respectively, to a similar degree (approximately four-
142 fold) compared with levels of endogenous Notch3 in non-transgenic mice [22]. The
143 transgene is integrated on the X chromosome, and random inactivation of 1 X
144 chromosome in females results in mosaic expression of the mutant protein in
145 TgNotch3^{R169C} female mice (Unpublished data). The mutation studied in our mice is
146 commonly seen in patients with CADASIL [26], however it is unclear whether similar
147 X-linked mosaic processes occur in humans. It has been suggested that men have
148 more severe disease than women, but underlying reasons remain unclear [10, 27]. In
149 our investigation, to avoid the confounding effects of mosaic expression in females,
150 we only studied male mice. Mice were housed in individual cages in a room with

151 controlled humidity and temperature (22°C - 24°C), and in light/dark cycles of 12 hours
152 with free access to food and tap water. They were studied at 24 weeks of age, at which
153 stage features consistent with CADASIL are well established and they exhibit features
154 of the human disease, as previously described [14, 16, 21, 22, 28]. For each set of
155 experiments, we used five to eight different mice. Mice were anaesthetized with 5%
156 isoflurane (1.5 L/min O₂). Blood was collected via cardiac puncture, which is a terminal
157 procedure, and tissues were collected for analysis. For each set of experiments, we
158 used five to eight different mice. Blood and tissues were collected for experiments.
159 Small mesenteric arteries were used to assess vascular function and molecular
160 studies. In previous study we demonstrated that this is a gain-of-function mutation,
161 where increased Notch3 signalling is observed in VSMCs and arteries. Body weight
162 and systolic blood pressure of TgNotch3^{R169C} mice were similar to wild-type
163 (TgNotch3^{WT}) controls. Cardiac function and structure were similar between groups.
164 Clinical features of subjects and mice phenotype were also shown previously [12].

165 **Transmission Electron Microscopy (TEM)**

166 GOM deposition in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice was
167 examined by transmission electron microscopy. Arteries (2 mm thick slices) were fixed
168 in 2% Glutaraldehyde / 2% Paraformaldehyde / 0.1M Sodium Cacodylate buffer
169 overnight at 4°C and rinsed with 0.1M Sodium Cacodylate buffer three times of 5
170 minutes before post fixation in 1% Osmium Tetroxide for 1 hour. Osmium Tetroxide
171 was removed with changes of distilled H₂O (dH₂O) three times of 10 minutes each.
172 Samples were then stained with 0.5% Uranyl Acetate / dH₂O for 1 hour in the dark
173 prior dehydration through an ethanol series of 30, 50, 70, 90% (15 minutes each),
174 100% ethanol (4 times of 5 minutes), dried 100% ethanol (plus 3A Molecular sieve) (4
175 times of 5 minutes), followed by three times changes of Propylene Oxide for 5 minutes

176 each. Samples were then placed into a mix of Propylene Oxide: EPON 812 resin 1:1
177 pure resin overnight, fresh resin embedded next day in moulds and polymerised at
178 60°C for 48 hours. Ultrathin sections (50-70 nm) were cut using a DRUKKER diamond
179 ultratome Knife and a LEICA Ultracut UTC. Sections were collected on Formvar
180 coated 100 mesh copper grids and contrast was stained with 2% Uranyl Acetate for 5
181 minutes and Reynolds Lead Citrate also for 5 minutes. Tissue samples were viewed
182 on a JEOL 1200EX TEM running at 80kv and digital images captured using a Cantega
183 2K X 2K camera and Olympus ITEM software.

184 **Vascular functional studies**

185 Mouse mesenteric resistance arteries (first and second order; ~300-350 μm) were
186 isolated from TgNotch3^{WT} and TgNotch3^{R169C} mice. Briefly, arterial segments were
187 mounted on isometric wire myographs (Danish Myo Technology, Denmark) filled with
188 5ml of physiological saline solution [(in mmol/L: 130 NaCl, 14.9 NaHCO₃, 4.7 KCl,
189 1.18KH₂PO₄, 1.17 MgSO₄.7H₂O, 5.5 glucose, 1.56 CaCl₂.2H₂O, and 0.026 EDTA] and
190 continuously gassed with a mixture of 95% O₂ and 5% CO₂ while being maintained at
191 a constant temperature of 37 \pm 0.5°C. Following 30 minutes of equilibration, the
192 contractile responses of arterial segments were assessed by the addition of KCl
193 (62.5mmol/L). The integrity of the endothelium was verified by relaxation induced by
194 acetylcholine (ACh) (3x10⁻⁶ mol/L) in arteries pre-contracted with thromboxane A₂
195 agonist (U46619) (3x10⁻⁸ mol/L). Endothelium-dependent relaxation was assessed as
196 a dose-response to acetylcholine (ACh, 10⁻⁹-10⁻⁵ mol/L). Endothelium-independent
197 vasorelaxation was assessed by a dose-response to sodium nitroprusside (SNP) (10⁻
198 10⁻⁵ mol/L), BAY 58-2667 (10⁻¹² – 10⁻⁵ mol/L) and 8-Bromoguanosine 3',5'-cyclic
199 monophosphate sodium salt (8-Br-cGMP) (10⁻⁸ – 10⁻⁴ mol/L). Concentration-response
200 curves to phenylephrine (Phe) (10⁻⁹ – 3x10⁻⁵ mol/L), U46619 (10⁻¹⁰ – 10⁻⁶ mol/L) and

201 angiotensin II (Ang II) (10^{-10} – 3×10^{-5} mol/L) were performed to evaluate
202 vasoconstriction. Vascular functional responses were also assessed in the absence
203 and presence of 4-Phenylbutyric acid (4-PBA) (ER stress inhibitor; 1 mmol/L, 30
204 minutes) or fasudil (Rho Kinase inhibitor; 1 μ mol/L, 30 minutes).

205 **Vascular smooth muscle cell isolation**

206 Methods for the isolation and culture of human VSMCs (from isolated small arteries
207 from gluteal biopsies) and mice (from mesenteric arteries) have been previously
208 described [24]. Briefly, cleaned arteries were placed in Ham's F-12 culture medium
209 containing 1% gentamicin, collagenase (type 1), elastase, soybean trypsin inhibitor
210 and BSA, and were incubated for 30 to 60 minutes at 37°C under constant agitation.
211 The digested tissue was further dissociated by repeated aspiration through a syringe
212 with 20G needle. The cell suspension was centrifuged (2000 rpm, 4 minutes) and the
213 cell pellet was resuspended in Ham's F-12 culture medium containing 10% FBS. Cells
214 were seeded onto 25mm flask. VSMCs were maintained in DMEM media
215 supplemented with 10% fetal bovine serum (FBS) and Penicillin/Streptomycin (50
216 μ g/ml). Before experimentation, cells were rendered quiescent by maintenance in a
217 reduced growth supplement medium (0.5% FBS) overnight. Only primary, low
218 passage cells (passages 4 to 8) were studied. In some protocols, the role of ER stress,
219 Rho kinase and Notch signalling was assessed using pharmacological inhibitors: ER
220 stress inhibitor, 4-phenylbutyrate (4-PBA, 1 mmol/L, Sigma-Aldrich, UK) and Rho
221 kinase inhibitor, fasudil (10 μ mol/L, Tocris, UK). Cells were pre-exposed to 4-PBA and
222 fasudil for 24 hours.

223 **Quantitative real-time Polymerase Chain Reaction**

224 Quantitative real-time Polymerase Chain Reaction (qPCR) (Qiagen, UK) was used to
225 assess mRNA expression in TgNotch3^{WT} and TgNotch3^{R169C} mice VSMCs and

226 mesenteric arteries. For some experiments, wildtype FVB mice were used as a control
227 for Notch3 and Notch3 target gene expression since TgNotch3^{WT} and TgNotch3^{R169C}
228 mice were on a FVB background. Briefly, total RNA was extracted from tissues using
229 TRIzol (Qiagen, Manchester, UK), treated with RNase-free DNase I, and 2 µg of RNA
230 was reverse transcribed in a reaction containing 100 µg/mL oligo-dT, 10 mmol/L of 2'-
231 deoxynucleoside 5'-triphosphate, 5×first-Strand buffer, and 2 µL of 200-U reverse
232 transcriptase. For real-time PCR amplification, 3 µL of each reverse transcription
233 product were diluted in a reaction buffer containing 5 µL of SYBR Green PCR master
234 mix and 300 nmol/L of primers in a final volume of 10 µL per sample. The reaction
235 conditions consisted of 2 steps at 50°C for 2 minutes and 95°C for 2 minutes, followed
236 by 40 cycles of 3 steps, 15-second denaturation at 95°C, 60-second annealing at
237 60°C, and 15 seconds at 72°C. Mouse primers used are detailed in supplementary
238 table S2. Data are expressed as target gene/GAPDH housekeeping gene. Relative
239 gene expression was calculated using the 2^{ΔΔCt} method.

240 **Measurement of intracellular Ca²⁺ transients in VSMCs**

241 VSMC Ca²⁺ signalling was assessed using the fluorescent Ca²⁺ indicator, Cal-520
242 acetoxymethyl ester (Cal-520/AM; Abcam; 10 µmol/L). Cells were grown in 12-well
243 plates and following removal of culture media were incubated with Cal-520 AM in 0.5%
244 FBS at 37°C for 75 minutes followed by 30 minutes at room temperature. Following
245 incubation, the dye solution was replaced with HEPES physiological saline solution
246 (1.3x10⁻¹ mol/L NaCl, 5x10⁻³ mol/L KCl, 10⁻³ mol/L CaCl, 10⁻³ mol/L MgCl, 2x10⁻² mol/L
247 HEPES, and 10⁻² mol/L D-glucose, pH 7.4) for 30 minutes prior to imaging.
248 Fluorescence intensity as a measure of [Ca²⁺]_i, was monitored for 30 seconds in basal
249 condition and 180 minutes under U46619 (1 µmol/L) stimulation. In some experiments,
250 VSMCs were pre-treated for 24 hours with 4-PBA. Fluorescence-based

251 measurements of Ca²⁺ signals were performed using an inverted epifluorescence
252 microscope (Axio Observer Z1 Live-Cell imaging system; Zeiss, Cambridge, UK) with
253 excitation/emission wavelengths 490/535nm, respectively. Images were acquired and
254 analysed using Zen Blue Program (Zeiss, Cambridge, UK).

255 **Immunoblotting**

256 Protein was extracted from mesenteric arteries isolated from TgNotch3^{WT} and
257 TgNotch3^{R169C} mice. Protein (30µg) was separated by electrophoresis on a
258 polyacrylamide gel and transferred to a nitrocellulose membrane. Non-specific binding
259 sites were blocked with 3% bovine serum albumin in Tris-buffered saline (TBS)
260 solution. Membranes were then incubated with specific antibodies overnight at 4°C.
261 Membranes were washed 3 times with TBS-Tween20 and incubated with infrared dye-
262 labelled secondary antibodies for 1 hour at room temperature. Membranes were
263 visualized using an Odyssey CLx infrared imaging system (LiCor Biosciences UK Ltd,
264 UK) and results were normalized to β-actin protein and are expressed in arbitrary units
265 compared to wildtype group, which was taken as 100. Antibodies used were as
266 follows: anti-β-actin (1:5000; Sigma-Aldrich, UK); anti-phospho-eNOS^{Thr495} (1:500;
267 Santa Cruz, UK); anti-phospho-eNOS^{Ser1177} (1:1000; Cell signalling, UK); anti-total-
268 eNOS (1:1000; Cell signalling, UK), anti-ERO1 (1:1000; Santa Cruz, UK).

269 **Affinity capture of sulfenylated proteins**

270 In order to investigate sGCβ1 oxidation, sulfenylated proteins were captured using a
271 biotin-tagged dimedone-based probe (DCP-Bio, Merck NS1226-5MG) that specifically
272 binds sulfenic acid groups (SOH) in proteins [29]. Mesenteric arteries from FVB,
273 TgNotch3^{WT} and TgNotch3^{R169C} mice and VSMC isolated from control and CADASIL
274 patients, after homogenization in lysis buffer were supplemented with DCP-Bio1
275 (1mM), N-methylmaleimide (10mM), catalase (200U) and protease inhibitors (1mM)

276 PMSF and 1 µg/mL of aprotinin, leupeptin and pepstatin). Samples were kept on ice
277 for 30 minutes and centrifuged at 12,000g for 4 minutes at 4°C. Supernatants were
278 collected and DCP-Bio1 excess was removed by acetone precipitation. The pellet was
279 washed in 70% acetone and suspended in non-supplemented lysis buffer. Protein
280 levels were determined, and 300 µg of total protein was added to a 50 µl slurry of non-
281 liganded support beads (sepharose CL-4B beads, Sigma-Aldrich, Seelze, Germany)
282 to remove proteins with a tendency to bind non-specifically and incubated for 2 hours
283 at 4°C with constant rotation. Beads were centrifuged at 1,000 x g for 2 minutes. The
284 supernatant was collected and incubated with streptavidin beads (High Capacity
285 Streptavidin–Agarose Resin, Thermo Scientific, Illinois, USA) overnight at 4°C with
286 constant rotation. After the incubation steps beads were centrifuged at 1,000 x g for 2
287 minutes and washed with PBS three times. Proteins were then eluted in 50 µl of 2x
288 sample buffer for western blotting and boiled at 95°C for 5 min. As a procedural control
289 for the affinity capture, it was used Biotinylated-Trx Loading Control Protein (Kerafast
290 EE0035). In order to concentrate the proteins for the protocol, a pool of five samples
291 from different mice or patients was made. Sulfenylated protein-enriched lysates were
292 used for immunoblotting and membranes were probed for sGCβ1 (anti-sGCβ1; 1:500;
293 Cayman Chemical, UK).

294 **Immunofluorescence**

295 Immune staining was performed for an endoplasmic reticulum (ER) stress regulator,
296 BiP, and 8-Hydroxyguanosine (8-OHG), an indirect oxidative stress marker. 8-OHG is
297 a modified guanosine that occurs in DNA/RNA due to attack by hydroxyl radicals that
298 are formed as by products and intermediates of aerobic metabolism and during
299 oxidative stress. 8-OHG immunohistochemistry has been widely used as a sensitive,
300 stable and integral biomarker of oxidative stress-induced DNA and RNA damage [30].

301 GRP78/BiP is a major ER chaperone protein critical for protein quality control of the
302 ER, regulating ER stress-signalling pathways leading to unfolded protein responses
303 (UPR) survival and apoptosis responses [31]. Paraffin sections (5 μ m) of brain from
304 control and CADASIL patients and mesenteric arteries from TgNotch3^{WT} and
305 TgNotch3^{R169C} mice were deparaffinized in xylene, rehydrated through graded ethanol,
306 and washed in water. All sections were incubated in EDTA (pH 8.0) and boiled for 15
307 minutes at 95°C for antigen unmasking. Slides were cooled to room temperature,
308 permeabilized in 0.5% Triton X-100 in phosphate-buffered saline (PBS) for 5 minutes,
309 and blocked with 10% donkey serum, 1% bovine serum albumin (BSA) in 1x Tris-
310 buffered saline and Tween 20 (TBS-T) for 1 hour at room temperature in a humidified
311 chamber. For 8-OHG immunostaining, slides were incubated overnight with anti- 8-
312 OHG goat polyclonal antibody (Abcam ab10802, 1:200 diluted in 5% donkey serum,
313 0.02% BSA, 0.0025% Tween-20 in 1x TBS solution) in a humidified chamber; and
314 Alexa-fluor-488-conjugated donkey anti-goat antibody (Molecular probes, A-11055,
315 1:300 dilution in 5% donkey, 0.02% BSA, 0.0025% Tween-20 in 1xTBS solution) was
316 used as secondary antibody. For BiP immunostaining, slides were incubated overnight
317 with anti-BiP rabbit antibody (Cell 3177, 1:200 diluted in 5% donkey serum, 0.02%
318 BSA, 0.0025% Tween-20 in 1x TBS solution) in a humidified chamber, and Alexa-
319 fluor-488-conjugated donkey anti-rabbit (Molecular probes, A-11034, 1:300 dilution in
320 5% donkey, 0.02% BSA, 0.0025% Tween-20 in 1xTBS solution) secondary antibody
321 was used. For both staining, after primary antibody incubation, secondary antibodies
322 were incubated for 1 hour at room temperature in the dark. Slides were treated with
323 0.1% Sudan Black B (Sigma Aldrich, 199664) in methanol for 10 minutes to minimise
324 autofluorescence. Sections were mounted with a coverslip using ProLong Gold anti-
325 fade mounting media containing DAPI (Molecular probes, P-36931) at room

326 temperature and then stored at 4°C in the dark. Fluorescence images were captured
327 at 20X (brain vessels from patients) or 63X (mesenteric arteries from mice)
328 magnification using an inverted epifluorescence microscope (Axio Observer Z1, Zeiss)
329 and a dedicated software (Zen Blue Program, Zeiss). Laser excitation and acquisition
330 settings were maintained constant across all slides. Image analyses were performed
331 using the software ImageJ®, where a mean of the green fluorescence intensity from at
332 least 3 vessels from each mice or patient was taken.

333 **cGMP ELISA**

334 Cyclic guanosine 3',5'-monophosphate (cGMP) levels were detected in this study in
335 VSMC isolated from TgNotch3^{WT} and TgNotch3^{R169C} mice and control and CADASIL
336 patients by ELISA assay according the manufacturer's protocol (Cyclic GMP Assay
337 kit, Cell Signaling Technology). Results were normalized by concentration of protein.

338 **Lucigenin-enhanced chemiluminescence**

339 Lucigenin-derived chemiluminescence assay was used to determine NADPH-
340 dependent ROS production in mesenteric arteries homogenates from TgNotch3^{WT} and
341 TgNotch3^{R169C} mice as we previously described [32]. Briefly, tissues were
342 homogenized in lysis buffer (20 mmol/L of KH₂PO₄, 1 mmol/L of EGTA, 1 µg/mL of
343 aprotinin, 1 µg/mL of leupeptin, 1 µg/mL of pepstatin, and 1 mmol/L of PMSF). 50 µl
344 of the sample were added to a suspension containing 175 µl of assay buffer (50
345 mmol/L of KH₂PO₄, 1 mmol/L of EGTA, and 150 mmol/L of sucrose) and lucigenin (5
346 µmol/L). Luminescence was measured with a luminometer (AutoLumat LB 953,
347 Berthold) before and after stimulation with nicotinamide adenine dinucleotide
348 phosphate (NADPH, 100 µmol/l). A buffer blank was subtracted from each reading.
349 Results were normalized by concentration of protein, as measured by the BCA assay.

350 **Amplex Red assay**

351 Hydrogen peroxide (H₂O₂) levels was assessed by Amplex red[®] assay in mesenteric
352 arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Protocols were made according to
353 the manufacture's instruction using the horseradish peroxidase-linked Amplex Red
354 fluorescence assay (A22188; Life Technologies). Fluorescence readings were made
355 in a 96-well plate at Ex/Em = 530/590 nm. H₂O₂ production was normalized to protein
356 concentration.

357 **Plasma TBARS measurement**

358 Blood was collected under isoflurane anesthesia (3% induction; 1.5% maintenance)
359 by cardiac puncture immediately prior to sacrifice. Blood was collected in heparinized
360 tubes (TekLab, County Durham, UK). Plasma was separated by centrifugation (2,000
361 rpm, 10 min) (Heraeus Megafuge 16R; ThermoScientific). Thiobarbituric acid reactive
362 substances (TBARS) are a well-established indicator of oxidative stress in cells,
363 plasma and tissues. Its products were detected in this study in plasma from
364 TgNotch3^{WT} and TgNotch3^{R169C} mice by colorimetric (532-535nm) assay according the
365 manufacturer's protocol (Cayman's TBARS Assay Kit, Cayman Chemical -
366 CAY700870).

367 **Urine biochemistry**

368 Spot urine was collected from the bladder during sacrifice. Urine were aliquoted, snap
369 frozen and stored at -80 °C. Albumin and creatinine were determined by an automated
370 analyzer (Roche/Hitachi cobas c systems - cobas c 311 Autoanalyser).

371 **Measurement of O₂^{•-} by electron paramagnetic resonance**

372 Superoxide anion (O₂^{•-}) was measured by electron paramagnetic resonance [33].
373 Production of O₂^{•-} was measured in in Krebs–Hepes buffer (99 mM NaCl, 4.69 mM
374 KCl, 2.5 mM CaCl₂·2H₂O, 1.2 mM MgSO₄·7H₂O, 25 mM NaHCO₃, 1.03 mM KH₂PO₄,

375 5.6 mM D (+) glucose, 20 mM HEPES, pH 7.4) containing chelating agents,
376 deferoxamine (25 μ M, Sigma) and sodium diethyldithiocarbamate trihydrate (5 μ M,
377 Sigma). Confluent cells were incubated with hydroxylamine spin probe 1-hydroxy-3-
378 methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH, 1 mM; Enzo Life Sciences) for
379 10 min at 37°C, and then washed with PBS. Then cells were collected and placed into
380 50 μ l glass capillary tubes (Hirschmann Laborgeräte, Eberstadt, Germany) and
381 subsequently assessed in an EPR spectrometer (e-scan Research Bruker® Biospin
382 Corporation) equipped with a super-high Q microwave cavity at room temperature.
383 Oxidation of CMH by $O_2^{\bullet-}$ results in formation of the stable nitroxide radical, 3-
384 methoxy-carbonyl (CM). Therefore, the amount of CM formed equals the
385 concentration of the reacting oxidant species. The concentration of CM was
386 determined from the amplitude of the low field component of EPR spectra according
387 to 1 mM stock solution of CMH dissolved in Krebs-HEPES buffer. Counts were
388 recorded once a minute for 10 minutes and $O_2^{\bullet-}$ formation recorded as μ mol/minute.
389 EPR spectra and kinetics were recorded from cell suspensions in 50 μ l. Instrument
390 settings were: field sweep, 50 G; microwave frequency, 9.78 GHz; microwave power,
391 20 mW; modulation amplitude, 2 G; conversion time, 656 ms; time constant, 656 ms;
392 512 points resolution and receiver gain, 1×10^5 . Results were normalized by protein
393 content.

394 **Statistical analysis**

395 For vascular functional studies, concentration-response curves were generated and
396 the maximal effect (E_{max}) and the agonist concentration that produced 50% of the
397 maximal response (log EC₅₀) were calculated using nonlinear regression analysis.
398 pD_2 (defined as the negative logarithm of the EC₅₀ values) and E_{max} were compared
399 by Student's *t*-test or two-way analysis of variance (ANOVA) with Bonferroni post-test,

400 as appropriate. For the other experiments, statistical comparisons between groups
401 were performed using two-tailed student's *t*-test and or one-way ANOVA. Bonferroni
402 or Dunnett post-test were used as appropriate. $p < 0.05$ was considered statistically
403 significant. Data analysis was conducted using GraphPad Prism[®] 6.0 (GraphPad
404 Software Inc., San Diego, CA). Data are expressed as mean \pm SEM.

405

406 **Results**

407 **GOM deposits in small peripheral arteries**

408 A characteristic feature of CADASIL is cerebrovascular GOM deposition [8]. GOM
409 deposits have been identified in VSMC in skin biopsies from CADASIL patients [34],
410 however whether GOM accumulates around VSMCs in peripheral small arteries is
411 unclear. As shown in figures 1A and 1B, electron microscopic analysis revealed GOM
412 deposits in mesenteric resistance arteries from TgNotch3^{R169C} mice but not in
413 TgNotch3^{WT} mice. GOM deposits were located close to the smooth muscle cells
414 (SMCs), often within an infolding of the cell membrane (Figure 1B, arrows). The
415 intercellular space between SMCs from TgNotch3^{R169C} mice is also enlarged when
416 compared to wildtype mice, which might be associated with increased deposition of
417 ECM components such as MMP2 and MMP9. Previous studies in cerebral vessels
418 from TgNotch3^{R169C} mice showed increased MMP expression [14, 21]. Here we
419 corroborate this in peripheral vessels, since mRNA expression of MMP2 and MMP9
420 was increased in CADASIL mice (Supplementary figure 2A, 2B).

421 **Altered vascular function of peripheral small arteries in CADASIL**

422 Small resistance arteries were studied by wire myography to assess vascular
423 contraction and relaxation. In small arteries from TgNotch3^{R169C} mice, contractile
424 responses to multiple vasoconstrictors including Phe, U46619 and Ang II were

425 increased compared with vessels from TgNotch3^{WT} mice (Supplementary figure 1A,
426 1B, 1C). These responses were restored when arteries were exposed to inhibitors of
427 Rho kinase (fasudil; Figures 2A, 2C, 2E) or ER stress (4-PBA; Figures 2B, 2D, 2F).
428 No changes were observed in vessels from TgNotch3^{WT} mice incubated with fasudil
429 or 4-PBA.

430 In addition to hypercontractile responses, CADASIL mice exhibited significantly
431 reduced endothelium-dependent (ACh-induced) and endothelium-independent
432 vasorelaxation (SNP-induced) compared with wildtype vessels (Figures 2G, 2H).
433 Maximum response for ACh-induced relaxation in TgNotch3^{R169C} was 73.7±3.9 versus
434 103.1±7.5 in TgNotch3^{WT} mice (p<0.05). EC₅₀ for SNP-induced vasorelaxation was
435 7.0±0.2 in TgNotch3^{R169C} versus 7.8±0.1 in wildtype mice (p<0.05). Pre-treatment of
436 vessels with 4-PBA normalized ACh-induced vasorelaxation in CADASIL mice (Figure
437 2G).

438 **Molecular mechanisms underlying vascular dysfunction in peripheral small** 439 **arteries in CADASIL**

440 To explore putative mechanisms underlying augmented vasoconstriction in CADASIL
441 vessels, we assessed some of the molecular machinery and signalling pathways that
442 control VSMC contraction. In particular we measured changes in agonist-stimulated
443 Ca²⁺ responses and Ca²⁺ channels and activation of the Rho kinase and ER stress
444 pathways in mesenteric arteries and VSMCs. As shown in figure 3, Ca²⁺ transients
445 and expression of various Ca²⁺ channels were altered in TgNotch3^{R169C}-derived
446 VSMCs, compared with wildtype VSMCs. Agonist-stimulated Ca²⁺ responses (Figure
447 3A) and the calculated area under the curve (Figure 3B) were significantly increased
448 in the TgNotch3^{R169C} group compared with control mice. Pre-treatment with 4-PBA
449 attenuated Ca²⁺ responses in CADASIL VSMCs. Gene expression of the Ca²⁺

450 channels voltage-dependent L-type calcium channel, subunit α_{1S} (*Cav1.1*), transient
451 receptor potential cation channel, subfamily M, member 2 (*TRPM2*) and ryanodine
452 receptor 1 (*RyR1*) was augmented in TgNotch3^{R169C}-derived VSMCs, whereas no
453 changes were observed for inositol 1,4,5-trisphosphate (IP_3) receptor (*IP3R*),
454 ryanodine receptor 2 (*RyR2*), ryanodine receptor 3 (*RyR3*) and sarcoplasmic reticulum
455 Ca^{2+} -ATPase (*SERCA*) (Figure 3C).

456 Having demonstrated that inhibitors of Rho kinase and ER stress ameliorate
457 hypercontractile responses in CADASIL vessels, some of the elements of these
458 systems were assessed. Vascular expression of the Rho guanine nucleotide-
459 exchange factors (GEFs), *Pdz* and *Larg*, was increased in TgNotch3^{R169C} mice
460 compared to TgNotch3^{WT} (Figure 4A). Gene expression of *p115* was unchanged in
461 TgNotch3^{R169C} mice. Arteries from TgNotch3^{R169C} mice also exhibited increased
462 transcription of ER stress genes: X-box binding protein 1 (*XBP1*), activating
463 transcription factor 4 (*ATF4*), binding immunoglobulin protein (*BiP*), and C/EBP
464 homologous protein (*CHOP*) (Figure 4B). Increased ER stress during Notch3 gain-of-
465 function mutation was confirmed in mesenteric arteries stained with BiP, a major ER
466 chaperone and a central regulator of ER stress, which was significantly increased in
467 TgNotch3^{R169C} vessels (Figure 4C). ERO1, a natural UPR target promoter triggered
468 by ER stress, was also increased in TgNotch3^{R169C} mesenteric arteries (Figure 4D).
469 Together these data indicate that a Notch3 gain-of-function mutation during CADASIL
470 is associated with upregulation of Rho kinase, ER stress responses and changes in
471 Ca^{2+} homeostasis in small peripheral arteries.

472 **Notch3 gain-of-function impairs NO signalling in peripheral small arteries**

473 Impaired vasorelaxation in TgNotch3^{R169C} mesenteric arteries was associated with
474 alterations in signalling pathways that control endothelial and vascular

475 contraction/dilation. As shown in figure 5A, phosphorylation of the inhibitory site of
476 endothelial nitric oxide synthase (eNOS; Thr⁴⁹⁵) was significantly increased in
477 TgNotch3^{R169C} mice whereas phosphorylation of the activator site of eNOS (Ser¹¹⁷⁷)
478 was unchanged (Supplementary figure 3). These responses were associated with
479 decreased cGMP levels in CADASIL VSMCs (Figure 5B). cGMP levels were not
480 altered by fasudil or 4-PBA in CADASIL and control VSMCs.

481 **Impaired vasorelaxation involves redox-sensitive PKG-dependent pathways in** 482 **TgNotch3^{R169C} mice**

483 To further dissect possible mechanisms underlying reduced vasorelaxation and
484 perturbed vascular NO/cGMP signalling in TgNotch3^{R169C} mice, we interrogated
485 vasodilator pathways mediated by redox-sensitive protein kinase G (PKG), which has
486 been shown to regulate vasorelaxation through H₂O₂-dependent pathways.
487 Vasorelaxation concentration-response curves to BAY 58-2667, a potent soluble
488 guanylyl cyclase (sGC) activator, and 8-Br-cGMP, which activates cGMP-dependent
489 PKG, were performed in mesenteric arteries from TgNotch3^{R169C} mice. Vasodilation
490 induced by both BAY 58-2667 (Figure 6A) and 8-Br-cGMP, a cGMP analogue (Figure
491 6B), was reduced in vessels from TgNotch3^{R169C} mice, suggesting an impairment in
492 sGC and PKG activity in these mice. At the molecular level, this was associated with
493 augmented generation of vascular ROS (Figure 6C, Supplementary figure 4B),
494 systemic oxidative stress (Supplementary figure 4A), increased oxidation of sGCβ1
495 (Figure 6D) and increased expression of Nox1 in TgNotch3^{R169C} arteries (Figure 6E).
496 No changes in Nox 2 and 4 were observed between groups (Supplementary figure 5).
497 Associated with increased NADPH-derived O₂^{•-} production was reduced bioavailability
498 of H₂O₂, a putative endothelium-derived relaxing factor (EDRF) [35, 36], in
499 TgNotch3^{R169C} arteries (Figure 6F). Vascular expression of the antioxidant enzymes

500 catalase and glutathione peroxidase 1 (GPX1), which catalyse H₂O₂ to O₂ and H₂O,
501 was increased in CADASIL mice (Figures 6G, 6H).

502 **Renal dysfunction in CADASIL mice**

503 To determine whether vascular abnormalities in CADASIL mice are associated with
504 altered organ function, we assessed renal function in CADASIL mice by measuring
505 urine albumin:creatinie ratio. TgNotch3^{R169C} mice also showed a significant increase
506 in albumin:creatinine ratio in urine, suggesting an increase in vascular permeability
507 and endothelial dysfunction (Figure 7).

508 **Impaired sGC/cGMP and oxidative status in VSMCs and cerebral vessels from** 509 **patients with CADASIL**

510 To determine whether the vascular alterations identified in experimental models of
511 CADASIL are also present in human vessels, we explored some of the molecular
512 processes in VSMCs from patients with CADASIL. We also studied post-mortem brain
513 sections from patients who had CADASIL. As shown in figure 7A, levels of cGMP, an
514 important regulator of VSMC relaxation, were significantly reduced in VSMCs from
515 patients with CADASIL. Pre-treatment of VSMCs with fasudil or 4-PBA normalised
516 cGMP levels (Figure 8A). Oxidation of sGCβ1 was higher in CADASIL VSMCs
517 compared with control VSMCs (Figure 8B). We previously showed that VSMCs from
518 CADASIL patients have increased oxidative stress [12]. Levels of DNA oxidation,
519 assessed as the 8-OHG content, were significantly increased in brain vessels in
520 CADASIL patients compared with controls (Figures 8C, 8D).

521

522 **Discussion**

523 CADASIL is typically associated with small vessel disease of the brain causing
524 migraine with aura, ischaemic structural changes in white and deep grey matter

525 structures, cognitive impairment, and recurrent small vessel ischemic strokes leading
526 to vascular dementia [7, 9]. However, growing pre-clinical and clinical evidence
527 indicates that peripheral small arteries are also dysfunctional in CADASIL [11, 37-39].
528 We recently reported that patients with CADASIL have impaired endothelial function
529 and altered vascular contractile responses, processes associated with increased Rho
530 kinase activation and ER stress [12]. To advance these findings and to further dissect
531 underlying molecular mechanisms we studied TgNotch3^{R169C} mice that express the
532 CADASIL-causing Notch3(R169C) mutant protein [22]. We also probed some
533 molecular processes in cerebral vessels in brain tissue obtained post-mortem from
534 patients with CADASIL. Major findings from our study show that peripheral small
535 arteries from TgNotch3^{R169C} mice exhibit GOM deposits, typically observed in the
536 cerebrovascular bed in CADASIL. Functional alterations were defined by
537 hypercontractility and impaired endothelium-dependent and -independent
538 vasorelaxation. At the molecular level, vascular abnormalities in TgNotch3^{R169C} mice
539 were linked to increased Ca²⁺ transients and upregulation of Ca²⁺ channels,
540 processes associated with Rho kinase activation and ER and oxidative stress. In
541 addition, we identified blunting of eNOS/NO/cGMP-induced vasorelaxation through
542 processes involving increased oxidation of sGC. These phenomena in mice were
543 recapitulated in human studies, where we observed increased oxidative stress-
544 induced DNA and RNA damage and sGC oxidation in VSMCs and cerebral arteries
545 from CADASIL patients. Exact processes linking Notch3 to perturbed vascular
546 signaling in CADASIL remain unclear, but oxidative stress may be a common driver
547 by promoting oxidation of downstream proteins.

548 Pathological hallmarks of the vasculopathy in CADASIL include accumulation
549 of the extracellular domain of Notch3 (Notch3^{ECD}) and the presence of GOM deposits

550 on SMCs from small arteries [40, 41]. In aging mice GOM deposits progress in size
551 over time and new GOM deposits are continuously being formed [41]. Here we
552 demonstrated by electron microscopy that peripheral arteries from TgNotch3^{R169C} mice
553 have GOM deposits, processes associated with altered ECM protein expression and
554 enlargement of SMC intercellular space in arteries. These findings recapitulate
555 features in cerebral vessels [40], confirming that manifestations of the Notch3 mutation
556 in CADASIL are not restricted to the cerebrovascular system but are likely present in
557 small arteries in multiple vascular beds [40].

558 We provide evidence that CADASIL-causing Notch3 mutations cause functional
559 changes in peripheral arteries. These process seem to be linked to the
560 pathophysiological manifestations of CADASIL because vascular changes only
561 become evident at 6 months when mice exhibit features of CADASIL, as previously
562 reported [22, 42]. In addition CADASIL mice exhibited some functional changes at the
563 kidney level because albumin:creatinine ratio was increased in TgNotch3^{R169C} mice.
564 Albuminuria represents increased endothelial permeability and dysfunction and is an
565 accepted cardiovascular risk factor clinically [43]. Proteinuria has also been described
566 in patients with CADASIL and may represent systemic vascular dysfunction in these
567 patients [44, 45].

568 Vasoconstriction to three different agonists (phenylephrine, Ang II and
569 U44619), was increased in TgNotch3^{R169C} mice, indicating a generalized phenomenon
570 rather than an agonist-specific effect. These findings are in contrast to what was
571 demonstrated in CADASIL patients where peripheral arteries showed reduced
572 vasoreactivity [11, 12, 46]. Reasons for these differences are unclear but may relate
573 to relative chronicity of the disease, since human studies were carried out in patients
574 later in life, whereas our experimental studies here were performed in mice at a

575 relatively young age (6 months). It may be possible that with aging and progression of
576 disease in TgNotch3^{R169C} mice, vasocontractile responses may change. However this
577 awaits confirmation. Vascular smooth muscle cell contraction is regulated primarily by
578 dynamic changes in Ca²⁺ homeostasis and Ca²⁺ channel activity/expression [47]. Our
579 findings showed hypercontractility of TgNotch3^{R169C} arteries, in addition to augmented
580 agonist-stimulated Ca²⁺ transients and increased expression of Ca²⁺ channels. These
581 processes are highly regulated since Cav1.1, IP3R and RyR1 were upregulated in
582 CADASIL mice, whereas TRPM2, SERCA, RyR2 and RyR3 were not altered
583 compared with control mice. Previous studies showed an important role for Notch in
584 Ca²⁺ regulation, since Notch increases expression/activity of store-operated Ca²⁺ entry
585 (SOCE) and canonical transient receptor potential (TRPC6) channels in VSMCs [48].
586 Moreover Ca²⁺ channel blockers seem to improve cognitive decline and cerebral
587 hypoperfusion in CADASIL patients [49], although this aspect warrants further
588 investigation.

589 Vascular smooth muscle cells are highly plastic and in disease states undergo
590 phenotypic switching from a contractile to a proliferative and pro-inflammatory state.
591 While VSMC contraction is triggered by an increase in [Ca²⁺]_i which promotes actin-
592 myosin interaction, it is also regulated by Ca²⁺-independent processes involving RhoA-
593 Rho kinase and MAP kinases, ROS amongst other systems [47]. These phenomena
594 are especially important in pathological conditions as we demonstrate here, where
595 vascular dysfunction was associated not only with amplification of Ca²⁺ transients, but
596 also with systems involving Rho kinase, oxidative and ER stress. Pharmacological
597 inhibitors of Rho kinase and ER stress normalised hypercontractile responses in
598 CADASIL mice, indicating involvement of these systems in Notch3-regulated
599 contraction. Supporting this notion, at the molecular level, elements of RhoA/Rho

600 kinase signalling, and the ER stress response were perturbed in TgNotch3^{R169C}
601 VSMCs. RhoA, a member of the Rho GTPase family and regulated by Rho GEFs, is
602 a master regulator of cytoskeletal dynamics and VSMC function [50, 51]. Expression
603 of Rho GEFs was altered in CADASIL mice. In particular, mRNA expression of PDZ
604 and LARG, but not p115, was increased in TgNotch3^{R169C} vessels. This is not
605 surprising since PDZ and LARG are crucial elements involved in VSMC contractile
606 signalling, whereas p115 influences destabilization of endothelial cell-cell junctions
607 [51]. Our findings are in line with those observed in VSMCs from CADASIL patients,
608 where the RhoA/Rho kinase pathway is upregulated [12].

609 Among the many systems implicated in abnormal VSMC function in CADASIL,
610 is abnormal handling and folding of mutant Notch3 protein, processes that involve the
611 ER [52]. Under stress conditions, proteins become misfolded and accumulate in the
612 ER provoking the unfolded ER protein response. Prolonged retention of ER mutant
613 Notch3 aggregates and ER stress influence VSMC function and GOM deposition and
614 may be important pathogenic mechanisms contributing to the vasculopathy in
615 CADASIL. Supporting this, expression of ER stress markers XBP1, ATF4, Bip, CHOP
616 and ERO1 was increased in CADASIL vessels, processes that involve Rho kinase
617 activation as we previously demonstrated [12]. ER stress is downstream of Rho kinase
618 because fasudil inhibits ER stress-induced responses by modulating the unfolded
619 protein response in vascular cells [53]. Functionally, ER stress influences vascular
620 function since 4-PBA attenuated hypercontractile responses in TgNotch3^{R169C} mice.
621 Corroborating these findings, previous studies showed that aberrant ER stress in
622 VSMCs causes increased vascular contraction [54].

623 Similar to what we found in peripheral and cerebral vessels in CADASIL
624 patients [12, 55], agonist-stimulated relaxation was impaired in mesenteric arteries in

625 TgNotch3^{R169C} mice. Both endothelium-dependent and endothelium-independent
626 vasorelaxation were reduced in CADASIL mice, analogous to what was reported in
627 the cerebrovascular system of these mice [42]. Endothelial NOS is the primary source
628 of NO in endothelial cells and is the key regulator of endothelial function [56]. Impaired
629 endothelium-dependent relaxation in TgNotch3^{R169C} arteries was associated with
630 decreased eNOS phosphorylation and oxidative stress, which lead to reduced eNOS
631 activation and decreased bioavailability of the vasodilator NO, which is vaso-injurious
632 [56]. Notch signalling plays an important role in cell-cell communication between
633 endothelial cells and VSMCs, but exactly how VSMC Notch3 influences endothelial
634 cell function remains unclear. It may be possible that endothelial injury is secondary
635 to VSMC dysfunction, vascular remodelling and GOM accumulation.

636 The importance of perturbed VSMC function in CADASIL is further evidenced
637 by our findings that endothelium-independent vasorelaxation (SNP-induced
638 responses) was impaired in TgNotch3^{R169C} mice. VSMCs constitute the bulk of the
639 vascular media and are largely responsible for maintaining vascular
640 contraction/dilation and arterial tone. The major molecular system controlling VSMC
641 dilation is the sGC/cGMP pathway. Activation of sGC increases production of the
642 second messenger cGMP, which influences downstream signalling through cGMP-
643 dependent protein kinase (PKG) [57, 58]. PKG is a potent vasodilator and mediates
644 effects in part through H₂O₂ [36]. PKG is also regulated by oxidant-induced interprotein
645 disulphide formation. This oxidation-induced activation of PKG represents an alternate
646 cGMP-independent mechanism regulating vascular function [59, 60]. The potential
647 role of sGC/cGMP/PKG in endothelium-independent vasorelaxation in CADASIL was
648 probed in VSMCs and vessels from TgNotch3^{R169C} mice and patients with CADASIL.
649 Vascular sensitivity to BAY 58-2667, a sGC activator that bypasses the impaired

650 NO/sGC/cGMP pathway by activating the oxidized form of the enzyme [61], was
651 reduced in TgNotch3^{R169C} mice, suggesting less activity of sGC due to its higher
652 oxidation. Supporting this, vascular oxidative stress, driven by Nox1-mediated ROS
653 production, and associated oxidation of sGC β 1 were increased in tissue from
654 TgNotch3^{R169C} mice. Decreased activation of sGC culminates in reduced PKG activity
655 and decreased vasodilation, which might be aggravated by decreased H₂O₂ levels,
656 since H₂O₂ is an important vasodilator [59, 60, 62]. This may be important in
657 TgNotch3^{R169C} mice, where downregulation of the sGC/cGMP system was associated
658 with decreased vascular H₂O₂ production compared with control mice. While these
659 observations were made in peripheral vessels, they are especially pertinent in the
660 cerebral circulation where H₂O₂ rather than NO seems to be the major vasodilator [36,
661 63]. Hence, cerebrovascular dysfunction in CADASIL may be linked, at least in part,
662 to defective H₂O₂-mediated vasorelaxation. Vascular H₂O₂ downregulation seems to
663 be associated with increased catalase and GPX1 whereas increased superoxide
664 levels may be linked to Nox1, an important source of vascular ROS [32].

665 Translating our pre-clinical studies to humans, we studied VSMCs and brain
666 sections from CADASIL patients and found increased vascular oxidative stress and
667 sGC β 1 oxidation and extensive DNA damage. These vascular abnormalities may play
668 a role in cerebrovascular pathology underlying CADASIL. Moreover, since many of the
669 vascular signaling pathways we studied are similarly dysregulated in patients with
670 CADASIL [12] and in our mouse model, we suggest that TgNotch3^{R169C} mice may be
671 a suitable experimental model of human disease.

672 In conclusion, we demonstrate that peripheral small arteries from
673 TgNotch3^{R169C} mice exhibit hypercontractility, impaired endothelium-dependent and -
674 independent vasorelaxation, processes associated with altered Ca²⁺ homeostasis,

675 upregulation of Rho kinase and ER stress. Moreover, we define novel pathways of
676 impaired eNOS/sGC/cGMP signalling in CADASIL through hyperoxidation, likely
677 driven by Nox1-mediated oxidative stress (Figure 9). Our data identify novel molecular
678 mechanisms whereby Notch3 gain-of-function mutation causes vascular dysfunction
679 and highlight the concept that, although the arteriopathy of CADASIL is primarily
680 cerebral, peripheral vessels are also affected. This has important clinical implications,
681 because systemic vasculopathy and dysfunctional vasoreactivity may be associated
682 with peripheral vascular disease in CADASIL patients [37]. Additionally, given the
683 current elusive knowledge of the downstream Notch3-mediated mechanisms in the
684 vasculature and the ubiquitous expression in all VSMCs, our data are not just useful
685 for examining CADASIL, but are translatable to vascular Notch3 signalling in general
686 and in other vascular diseases.

687

688 **Data availability Statement**

689 The data underlying this study will be shared on request to the corresponding author.

690

691 **Clinical Perspectives**

692 • **Background as to why the study was undertaken**

693 CADASIL is typically defined as a small vessel disease of the brain. However growing
694 evidence indicates that peripheral small vessels are also dysfunctional, which may be
695 a marker of cerebral vessel dysfunction and/or contribute to peripheral vascular
696 disease. Molecular mechanisms underlying the peripheral vasculopathy in CADASIL
697 remain unclear, although Rho kinase and ER- and oxidative stress may be important
698 as we showed. Here we advance this notion and define novel signaling cascades in the

699 vasculopathy of CADASIL, particularly related to interplay between oxidative stress
700 and the eNOS/NO/sGC/cGMP pathway.

701 **A brief summary of the results**

702 CADASIL mice with Notch3 gain of function mutation exhibit peripheral vascular
703 dysfunction characterised by impaired vasorelaxation and hypercontractility. These
704 processes involve altered vascular Ca²⁺ homeostasis, upregulation of Rho kinase, and
705 ER- and Nox1-mediated oxidative stress that cause hyperoxidation of vascular
706 signaling molecules and blunting of the eNOS/sGC/cGMP pathway. Findings in
707 CADASIL mice were recapitulated in post-mortem cerebral vessels from patients with
708 CADASIL

709 **The potential significance of the results to human health and disease**

710 We identify novel pathways whereby Notch3 gain-of-function mutation causes
711 vascular dysfunction and highlight the concept that, although the arteriopathy of
712 CADASIL is primarily cerebral, peripheral vessels are also affected. This has important
713 clinical implications, because systemic vasculopathy may predispose to peripheral
714 vascular disease in CADASIL patients. Additionally, given the gap in knowledge of
715 Notch3-mediated downstream pathways and the ubiquitous expression in VSMCs, our
716 data provide insights into vascular Notch3 signalling in general, beyond CADASIL.

717 718 **Competing Interests**

719 None.

720

721 **Funding**

722 This study was supported by grants from the British Heart Foundation (BHF)
723 (RE/13/5/30177; 18/6/34217) and the MRC (MC-PC-15076). The CADASIL biopsy
724 samples were funded by grants from The Neurosciences Foundation and The Stroke

725 Association (TSA 2013/02) and the control biopsy samples were funded by grants from
726 the Department of Medicine, University of Ottawa and the Canadian Institutes of
727 Health Research, Canada. RMT is supported through a BHF Chair award
728 (CH/12/29762) and ACM is supported through a Walton Foundation fellowship,
729 University of Glasgow.

730

731 **Acknowledgments**

732 Our sincere thanks to Prof. Anne Joutel, who kindly provided the CADASIL mouse
733 model. Thanks to Dr Willie Stewart for expert help with the neuropathology (Institute
734 of Neuroscience & Psychology, University of Glasgow & Queen Elizabeth University
735 Hospital). We thank Margaret Mullen for all support with the electron microscopy
736 experiments; Dr Adam Harvey and Wendy Beattie for the help with the human cells
737 and mouse colonies; Laura Haddow and John McAbeny from the BHF Myography &
738 Imaging Core Facility; Jackie Thomson and Ross Hepburn for all the lab support. We
739 are also very grateful to the patients and volunteers who participated in this study. We
740 acknowledge the support of NHS Research Scotland (NRS), NHS Greater Glasgow
741 and Clyde Biorepository.

742

743 **Abbreviations**

744 CADASIL – Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
745 Leukoencephalopathy

746 Notch3^{ECD} - extracellular domain of Notch3

747 GOM - granular osmiophilic material

748 VSMC - vascular smooth muscle cells

749 ER - endoplasmic reticulum

- 750 sGC – soluble guanylate cyclase
- 751 NO – nitric oxide
- 752 eNOS – endothelial nitric oxide synthase
- 753 cGMP – cyclic guanosine monophosphate
- 754 Kv1 - voltage-dependent potassium (Kv1) channels
- 755 ROS - reactive oxygen species
- 756 FBS - fetal bovine serum
- 757 4-PBA - 4-phenylbutyrate
- 758 SOH - sulfenic acid groups
- 759 8-OHG - 8-Hydroxyguanosine
- 760 UPR - unfolded protein responses
- 761 H₂O₂ - Hydrogen peroxide
- 762 TBARS - Thiobarbituric acid reactive substances
- 763 ACh – acetylcholine
- 764 SNP – sodium nitroprusside
- 765 Phe - phenylephrine
- 766 Cav1.1 - Ca²⁺ channels voltage-dependent L-type calcium channel, subunit α_{1S}
- 767 TRPM2 - transient receptor potential cation channel, subfamily M, member 2
- 768 RyR - ryanodine receptor
- 769 IP₃R - inositol 1,4,5-trisphosphate
- 770 SERCA - sarcoplasmic reticulum Ca²⁺-ATPase
- 771 GEFs - guanine nucleotide-exchange factors
- 772 XBP1 - X-box binding protein 1
- 773 ATF4 - activating transcription factor 4
- 774 BiP - binding immunoglobulin protein

775 CHOP - C/EBP homologous protein
776 GPX1 - glutathione peroxidase 1
777 SOCE - store-operated Ca²⁺ entry (SOCE)
778 TRPC6 - canonical transient receptor potential

779

780 References

- 781 1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control
782 and signal integration in development. *Science*. 1999;**284**:770-776
- 783 2. Fleming RJ. Structural conservation of notch receptors and ligands. *Semin*
784 *Cell Dev Biol*. 1998;**9**:599-607
- 785 3. Kopan R, Ilagan MX. The canonical notch signaling pathway: Unfolding the
786 activation mechanism. *Cell*. 2009;**137**:216-233
- 787 4. Morris HE, Neves KB, Montezano AC, MacLean MR, Touyz RM. Notch3
788 signalling and vascular remodelling in pulmonary arterial hypertension. *Clin*
789 *Sci (Lond)*. 2019;**133**:2481-2498
- 790 5. Baeten JT, Lilly B. Notch signaling in vascular smooth muscle cells. *Adv*
791 *Pharmacol*. 2017;**78**:351-382
- 792 6. Wang T, Baron M, Trump D. An overview of notch3 function in vascular
793 smooth muscle cells. *Prog Biophys Mol Biol*. 2008;**96**:499-509
- 794 7. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P,
795 Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere
796 C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser
797 MG, Tournier-Lasserre E. Notch3 mutations in cadasil, a hereditary adult-
798 onset condition causing stroke and dementia. *Nature*. 1996;**383**:707-710
- 799 8. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3
800 ectodomain is a major component of granular osmiophilic material (gom) in
801 cadasil. *Acta Neuropathol*. 2006;**112**:333-339
- 802 9. Moreton FC, Razvi SS, Davidson R, Muir KW. Changing clinical patterns and
803 increasing prevalence in cadasil. *Acta Neurol Scand*. 2014;**130**:197-203
- 804 10. Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M,
805 Jouvent E, Korczyn AD, Lesnik-Oberstein SA, Malandrini A, Markus HS,
806 Pantoni L, Penco S, Rufa A, Sinanovic O, Stojanov D, Federico A. Cerebral
807 autosomal dominant arteriopathy with subcortical infarcts and
808 leukoencephalopathy (cadasil) as a model of small vessel disease: Update on
809 clinical, diagnostic, and management aspects. *BMC Med*. 2017;**15**:41
- 810 11. Moreton FC, Cullen B, Delles C, Santosh C, Gonzalez RL, Dani K, Muir KW.
811 Vasoreactivity in cadasil: Comparison to structural mri and neuropsychology.
812 *J Cereb Blood Flow Metab*. 2018;**38**:1085-1095
- 813 12. Neves KB, Harvey AP, Moreton F, Montezano AC, Rios FJ, Alves-Lopes R,
814 Nguyen Dinh Cat A, Rocchiccioli P, Delles C, Joutel A, Muir K, Touyz RM. Er
815 stress and rho kinase activation underlie the vasculopathy of cadasil. *JCI*
816 *Insight*. 2019;**4**
- 817 13. Ling C, Liu Z, Song M, Zhang W, Wang S, Liu X, Ma S, Sun S, Fu L, Chu Q,
818 Belmonte JCI, Wang Z, Qu J, Yuan Y, Liu GH. Modeling cadasil vascular

- 819 pathologies with patient-derived induced pluripotent stem cells. *Protein Cell*.
820 2019;**10**:249-271
- 821 14. Capone C, Dabertrand F, Baron-Menguy C, Chalaris A, Ghezali L, Domenga-
822 Denier V, Schmidt S, Huneau C, Rose-John S, Nelson MT, Joutel A.
823 Mechanistic insights into a timp3-sensitive pathway constitutively engaged in
824 the regulation of cerebral hemodynamics. *Elife*. 2016;**5**
- 825 15. Ihalainen S, Soliymani R, Iivanainen E, Mykkanen K, Sainio A, Poyhonen M,
826 Elenius K, Jarvelainen H, Viitanen M, Kalimo H, Baumann M. Proteome
827 analysis of cultivated vascular smooth muscle cells from a cadasil patient. *Mol*
828 *Med*. 2007;**13**:305-314
- 829 16. Monet-Lepretre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M, Riani M,
830 Domenga-Denier V, Dussaule C, Cognat E, Vinh J, Joutel A. Abnormal
831 recruitment of extracellular matrix proteins by excess notch3 ecd: A new
832 pathomechanism in cadasil. *Brain*. 2013;**136**:1830-1845
- 833 17. Dong H, Blaivas M, Wang MM. Bidirectional encroachment of collagen into
834 the tunica media in cerebral autosomal dominant arteriopathy with subcortical
835 infarcts and leukoencephalopathy. *Brain Res*. 2012;**1456**:64-71
- 836 18. Panahi M, Yousefi Mesri N, Samuelsson EB, Coupland KG, Forsell C, Graff
837 C, Tikka S, Winblad B, Viitanen M, Karlstrom H, Sundstrom E, Behbahani H.
838 Differences in proliferation rate between cadasil and control vascular smooth
839 muscle cells are related to increased tgfbeta expression. *J Cell Mol Med*.
840 2018;**22**:3016-3024
- 841 19. Tikka S, Ng YP, Di Maio G, Mykkanen K, Siitonen M, Lepikhova T, Poyhonen
842 M, Viitanen M, Virtanen I, Kalimo H, Baumann M. Cadasil mutations and
843 shrna silencing of notch3 affect actin organization in cultured vascular smooth
844 muscle cells. *J Cereb Blood Flow Metab*. 2012;**32**:2171-2180
- 845 20. Viitanen M, Sundstrom E, Baumann M, Poyhonen M, Tikka S, Behbahani H.
846 Experimental studies of mitochondrial function in cadasil vascular smooth
847 muscle cells. *Exp Cell Res*. 2013;**319**:134-143
- 848 21. Dabertrand F, Kroigaard C, Bonev AD, Cognat E, Dalsgaard T, Domenga-
849 Denier V, Hill-Eubanks DC, Brayden JE, Joutel A, Nelson MT. Potassium
850 channelopathy-like defect underlies early-stage cerebrovascular dysfunction
851 in a genetic model of small vessel disease. *Proc Natl Acad Sci U S A*.
852 2015;**112**:E796-805
- 853 22. Baron-Menguy C, Domenga-Denier V, Ghezali L, Faraci FM, Joutel A.
854 Increased notch3 activity mediates pathological changes in structure of
855 cerebral arteries. *Hypertension*. 2017;**69**:60-70
- 856 23. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure
857 and endothelial dysfunction in human essential hypertension by the
858 angiotensin receptor antagonist losartan. *Circulation*. 2000;**101**:1653-1659
- 859 24. Montezano AC, Lopes RA, Neves KB, Rios F, Touyz RM. Isolation and
860 culture of vascular smooth muscle cells from small and large vessels.
861 *Methods Mol Biol*. 2017;**1527**:349-354
- 862 25. Graham DI, Gentleman SM, Lynch A, Roberts GW. Distribution of beta-
863 amyloid protein in the brain following severe head injury. *Neuropathol Appl*
864 *Neurobiol*. 1995;**21**:27-34
- 865 26. Paraskevas GP, Bougea A, Synetou M, Vassilopoulou S, Anagnostou E,
866 Voumvourakis K, Iliopoulos A, Spengos K. Cadasil and autoimmunity:
867 Coexistence in a family with the r169c mutation at exon 4 of the notch3 gene.
868 *Cerebrovasc Dis*. 2014;**38**:302-307

- 869 27. Rutten JW, Hack RJ, Duering M, Gravesteijn G, Dauwerse JG, Overzier M,
870 van den Akker EB, Slagboom E, Holstege H, Nho K, Saykin A, Dichgans M,
871 Malik R, Lesnik Oberstein SAJ. Broad phenotype of cysteine-altering notch3
872 variants in uk biobank: Cadasil to nonpenetrance. *Neurology*. 2020;**95**:e1835-
873 e1843
- 874 28. Lacombe P, Oligo C, Domenga V, Tournier-Lasserre E, Joutel A. Impaired
875 cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal
876 dominant arteriopathy with subcortical infarcts and leukoencephalopathy
877 arteriopathy. *Stroke*. 2005;**36**:1053-1058
- 878 29. Nelson KJ, Klomsiri C, Codreanu SG, Soito L, Liebler DC, Rogers LC, Daniel
879 LW, Poole LB. Use of dimedone-based chemical probes for sulfenic acid
880 detection methods to visualize and identify labeled proteins. *Methods*
881 *Enzymol*. 2010;**473**:95-115
- 882 30. Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootsuyama A, Tanooka H.
883 Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing
884 oxygen radicals and evidence for its repair. *Carcinogenesis*. 1986;**7**:1849-
885 1851
- 886 31. Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein
887 response regulator grp78/bip in development, cancer, and neurological
888 disorders. *Antioxid Redox Signal*. 2009;**11**:2307-2316
- 889 32. Lopes RA, Neves KB, Tostes RC, Montezano AC, Touyz RM. Downregulation
890 of nuclear factor erythroid 2-related factor and associated antioxidant genes
891 contributes to redox-sensitive vascular dysfunction in hypertension.
892 *Hypertension*. 2015;**66**:1240-1250
- 893 33. Dikalov SI, Kirilyuk IA, Voinov M, Grigor'ev IA. Epr detection of cellular and
894 mitochondrial superoxide using cyclic hydroxylamines. *Free Radic Res*.
895 2011;**45**:417-430
- 896 34. Lorenzi T, Ragno M, Paolinelli F, Castellucci C, Scarpelli M, Morrioni M.
897 Cadasil: Ultrastructural insights into the morphology of granular osmiophilic
898 material. *Brain Behav*. 2017;**7**:e00624
- 899 35. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K,
900 Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived
901 hyperpolarizing factor in mice. *J Clin Invest*. 2000;**106**:1521-1530
- 902 36. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing
903 factor. *Pflugers Arch*. 2010;**459**:915-922
- 904 37. Briceno DF, Bhattacharjee MB, Supsupin E, Jr., Navarro P, Bhattacharjee M.
905 Peripheral artery disease as a manifestation of cerebral autosomal dominant
906 arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) and
907 practical implications. *Circulation*. 2013;**127**:e568-570
- 908 38. Fujiwara Y, Mizuno T, Okuyama C, Nagakane Y, Watanabe-Hosomi A, Kondo
909 M, Kuriyama N, Tokuda T, Matsushima S, Nishimura T, Nakagawa M.
910 Simultaneous impairment of intracranial and peripheral artery vasoreactivity in
911 cadasil patients. *Cerebrovasc Dis*. 2012;**33**:128-134
- 912 39. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial
913 function of forearm resistance arteries in cadasil patients. *Stroke*.
914 2007;**38**:2692-2697
- 915 40. Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserre
916 E, Joutel A. Transgenic mice expressing mutant notch3 develop vascular
917 alterations characteristic of cerebral autosomal dominant arteriopathy with
918 subcortical infarcts and leukoencephalopathy. *Am J Pathol*. 2003;**162**:329-342

- 919 41. Gravesteijn G, Munting LP, Overzier M, Mulder AA, Hegeman I, Derieppe M,
920 Koster AJ, van Duinen SG, Meijer OC, Aartsma-Rus A, van der Weerd L, Jost
921 CR, van den Maagdenberg A, Rutten JW, Lesnik Oberstein SAJ. Progression
922 and classification of granular osmiophilic material (gom) deposits in
923 functionally characterized human notch3 transgenic mice. *Transl Stroke Res.*
924 2019
- 925 42. Capone C, Cognat E, Ghezali L, Baron-Menguy C, Aubin D, Mesnard L, Stohr
926 H, Domenga-Denier V, Nelson MT, Joutel A. Reducing timp3 or vitronectin
927 ameliorates disease manifestations in cadasil mice. *Ann Neurol.* 2016;**79**:387-
928 403
- 929 43. Paisley KE, Beaman M, Tooke JE, Mohamed-Ali V, Lowe GD, Shore AC.
930 Endothelial dysfunction and inflammation in asymptomatic proteinuria. *Kidney*
931 *Int.* 2003;**63**:624-633
- 932 44. Ragno M, Trojano L, Pianese L, Boni MV, Silvestri S, Mambelli V, Lorenzi T,
933 Scarpelli M, Morroni M. Renal involvement in cerebral autosomal dominant
934 arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil):
935 Report of a case with a six-year follow-up. *Histol Histopathol.* 2012;**27**:1307-
936 1314
- 937 45. Kusaba T, Hatta T, Kimura T, Sonomura K, Tanda S, Kishimoto N,
938 Kameyama H, Okigaki M, Mori Y, Ishigami N, Mizuno T, Nakagawa M,
939 Matsubara H. Renal involvement in cerebral autosomal dominant arteriopathy
940 with subcortical infarcts and leukoencephalopathy (cadasil). *Clin Nephrol.*
941 2007;**67**:182-187
- 942 46. Hussain MB, Singhal S, Markus HS, Singer DR. Abnormal vasoconstrictor
943 responses to angiotensin ii and noradrenaline in isolated small arteries from
944 patients with cerebral autosomal dominant arteriopathy with subcortical
945 infarcts and leukoencephalopathy (cadasil). *Stroke.* 2004;**35**:853-858
- 946 47. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner
947 A, Montezano AC. Vascular smooth muscle contraction in hypertension.
948 *Cardiovasc Res.* 2018;**114**:529-539
- 949 48. Smith KA, Voirit G, Tang H, Fraidenburg DR, Song S, Yamamura H,
950 Yamamura A, Guo Q, Wan J, Pohl NM, Tauseef M, Bodmer R, Ocorr K,
951 Thistlethwaite PA, Haddad GG, Powell FL, Makino A, Mehta D, Yuan JX.
952 Notch activation of ca(2+) signaling in the development of hypoxic pulmonary
953 vasoconstriction and pulmonary hypertension. *Am J Respir Cell Mol Biol.*
954 2015;**53**:355-367
- 955 49. Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, Isayama
956 R, Hosomi A, Nagakane Y, Tokuda T, Sugimoto E, Ushijima Y, Nakagawa M.
957 Cognitive impairment and cerebral hypoperfusion in a cadasil patient
958 improved during administration of lomerizine. *Clin Neuropharmacol.*
959 2009;**32**:113-116
- 960 50. van Buul JD, Geerts D, Huveneers S. Rho gaps and gefs: Controlling switches
961 in endothelial cell adhesion. *Cell Adh Migr.* 2014;**8**:108-124
- 962 51. Hodge RG, Ridley AJ. Regulating rho gtpases and their regulators. *Nat Rev*
963 *Mol Cell Biol.* 2016;**17**:496-510
- 964 52. Takahashi K, Adachi K, Yoshizaki K, Kunimoto S, Kalaria RN, Watanabe A.
965 Mutations in notch3 cause the formation and retention of aggregates in the
966 endoplasmic reticulum, leading to impaired cell proliferation. *Hum Mol Genet.*
967 2010;**19**:79-89

- 968 53. Kawanami D, Matoba K, Okada R, Tsukamoto M, Kinoshita J, Ishizawa S,
969 Kanazawa Y, Yokota T, Utsunomiya K. Fasudil inhibits er stress-induced
970 vcam-1 expression by modulating unfolded protein response in endothelial
971 cells. *Biochem Biophys Res Commun*. 2013;**435**:171-175
- 972 54. Liang B, Wang S, Wang Q, Zhang W, Viollet B, Zhu Y, Zou MH. Aberrant
973 endoplasmic reticulum stress in vascular smooth muscle increases vascular
974 contractility and blood pressure in mice deficient of amp-activated protein
975 kinase-alpha2 in vivo. *Arterioscler Thromb Vasc Biol*. 2013;**33**:595-604
- 976 55. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K,
977 Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in cadasil before
978 and after acetazolamide challenge assessed with mri bolus tracking. *Stroke*.
979 2000;**31**:1904-1912
- 980 56. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular
981 disease: From marvel to menace. *Circulation*. 2006;**113**:1708-1714
- 982 57. Park M, Sandner P, Krieg T. Cgmp at the centre of attention: Emerging
983 strategies for activating the cardioprotective pkg pathway. *Basic Res Cardiol*.
984 2018;**113**:24
- 985 58. Cuello F, Eaton P. Cysteine-based redox sensing and its role in signaling by
986 cyclic nucleotide-dependent kinases in the cardiovascular system. *Annu Rev*
987 *Physiol*. 2019;**81**:63-87
- 988 59. Dou D, Zheng X, Liu J, Xu X, Ye L, Gao Y. Hydrogen peroxide enhances
989 vasodilatation by increasing dimerization of cgmp-dependent protein kinase
990 type ialpha. *Circ J*. 2012;**76**:1792-1798
- 991 60. Sheehe JL, Bonev AD, Schmoker AM, Ballif BA, Nelson MT, Moon TM,
992 Dostmann WR. Oxidation of cysteine 117 stimulates constitutive activation of
993 the type ialpha cgmp-dependent protein kinase. *J Biol Chem*.
994 2018;**293**:16791-16802
- 995 61. Shah RC, Sanker S, Wood KC, Durgin BG, Straub AC. Redox regulation of
996 soluble guanylyl cyclase. *Nitric Oxide*. 2018;**76**:97-104
- 997 62. Stubbert D, Prysyazhna O, Rudyk O, Scotcher J, Burgoyne JR, Eaton P.
998 Protein kinase g ialpha oxidation paradoxically underlies blood pressure
999 lowering by the reductant hydrogen sulfide. *Hypertension*. 2014;**64**:1344-1351
- 1000 63. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by
1001 superoxide, hydrogen peroxide, and peroxynitrite. *Am J Physiol*.
1002 1996;**271**:H1262-1266
- 1003

1004

1005

1006 **Figures and Figure Legends**

1007 **Figure 1. GOM deposition in CADASIL peripheral small arteries.** GOM deposits
1008 were identified in mesenteric arteries from 24-week-old TgNotch3^{WT} and
1009 TgNotch3^{R169C} mice via electron microscopy. Ultrathin vessel sections from
1010 TgNotch3^{WT} (A) and TgNotch3^{R169C} (B) mice were examined by electron microscopy
1011 (n=2). Vessels from TgNotch3^{R169C} exhibited electron-dense granular deposits
1012 corresponding to GOM (arrows) within the basement membrane. SMC, smooth
1013 muscle cell; EC, endothelial cell; BM, basal membrane. Magnification 600x; Scale bar
1014 5 μ m.

1015

1016 **Figure 2. Role of Rho kinase signalling pathway and ER stress in the vascular**
1017 **dysfunction observed in TgNotch3^{R169C} peripheral small arteries.** Vascular
1018 functional responses in mesenteric arteries obtained from 24-week-old TgNotch3^{WT}
1019 and TgNotch3^{R169C} in response to phenylephrine (Phe), U46619, Angiotensin II (Ang
1020 II), acetylcholine (ACh) and sodium nitroprusside (SNP) was assessed by wire
1021 myography. The increase in contraction observed in TgNotch3^{R169C} mice was
1022 ameliorated in vessels pre-treated with the Rho kinase inhibitor fasudil (A, C, E) and
1023 the ER stress inhibitor 4-PBA (B, D, F) (n=5-6; Two-way ANOVA with Bonferroni post-
1024 test). Curves represent the mean \pm SEM. (G) Endothelium-dependent vasorelaxation
1025 in response to acetylcholine (ACh) was decreased in TgNotch3^{R169C} vessels, which
1026 was improved by the ER stress inhibitor 4-PBA (n=4-5). (H) Endothelium-independent
1027 vasorelaxation in response to sodium nitroprusside (SNP) was decreased in
1028 TgNotch3^{R169C} vessels (n=9-12). Responses were expressed as percentage of
1029 U46619-induced pre-constriction. Curves represent the mean \pm SEM. Two-way
1030 ANOVA with Bonferroni post-test. # p<0.05 vs. TgN3^{WT}, † vs. TgN3^{R169C}.

1031

1032 **Figure 3. Increased $[Ca^{2+}]_i$ transients and Ca^{2+} channels gene expression in**
1033 **TgNotch3^{R169C} VSMCs.** (A) Calcium transients were measured by live cell
1034 fluorescence imaging using the fluoroprobe Cal-520 AM. Representative tracings of
1035 VSMCs $[Ca^{2+}]_i$ responses to U46619 (1 μ mol/L) in TgNotch3^{WT} and TgNotch3^{R169C}
1036 VSMCs in presence or absence of 4-PBA. Experiments were repeated 6 times/group
1037 with >30 cells studied/field. (B) $[Ca^{2+}]_i$ calculated as the area under the curve (n=6;
1038 One-way ANOVA with Dunnett post-test). (C) *Cav1.1*, *TRPM2*, *IP3R*, *SERCA*, *RyR1*,
1039 *RyR2* and *RyR3* gene expression in VSMCs isolated from TgNotch3^{WT} and
1040 TgNotch3^{R169C} mice. Analysis was by qPCR and gene expression was normalised to
1041 GAPDH (n=5-11; One-way ANOVA with Dunnett post-test). Results are expressed as
1042 mean \pm SEM. # p<0.05 vs. TgN3^{WT}, † vs. TgN3^{R169C}.

1043

1044 **Figure 4. Rho kinase and ER stress markers are increased in TgNotch3^{R169C}**
1045 **arteries.** (A) *PDZ*, *LARG* and *p115* gene expression in mesenteric arteries from FVB,
1046 TgNotch3^{WT} and TgNotch3^{R169C} mice (n=6-8). (B) *XBP1*, *ATF4*, *BiP* and *CHOP* gene
1047 expression in FVB, TgNotch3^{WT} and TgNotch3^{R169C} mice (n=5-8). Analysis was
1048 performed by qPCR and gene expression was normalised to GAPDH (One-way
1049 ANOVA with Dunnett post-test). (C) Representative images and fluorescence
1050 quantification of BiP (ER stress marker) in mesenteric arteries from 24-week-old
1051 TgNotch3^{WT} and TgNotch3^{R169C} mice. Nuclei are in blue (DAPI) and BiP in green.
1052 Scale bars = 20 μ m; 63x (n=4; Student's *t* test). (D) Upper panel: representative
1053 immunoblot for ERO1 in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C}
1054 mice; Lower panels: quantification of ERO1. Protein expression was normalised to β -
1055 actin. Results are expressed as mean \pm SEM *p<0.05 vs FVB, # vs. TgN3^{WT}.

1056

1057 **Figure 5. Vasodilation impairment in TgNotch3^{R169C} arteries involves**

1058 **downregulation of eNOS activity and cGMP levels.** (A) Upper panel: representative

1059 immunoblot for the phosphorylation of the inhibitory site of eNOS (Thr⁴⁹⁵) in mesenteric

1060 arteries from 24-week-old TgNotch3^{WT} and TgNotch3^{R169C} mice; Lower panels:

1061 quantification of p-eNOS. Protein expression was normalised to t-eNOS (n=7;

1062 Student's *t* test). (B) Levels of cGMP in VSMCs isolated from TgNotch3^{WT} and

1063 TgNotch3^{R169C} mice in presence or absence of fasudil and 4-PBA (n=5-9; One-way

1064 ANOVA with Dunnett post-test). Results are expressed as mean±SEM. # *p*<0.05 vs.

1065 TgN3^{WT}.

1066

1067 **Figure 6. Downregulation of NO/sGC/cGMP signalling pathway in VSMCs during**

1068 **Notch3 gain-of-function mutation is associated with redox-sensitive processes.**

1069 Concentration-response curves to (A) BAY 58-2667 (sGC activator) and (B) 8-Br-

1070 cGMP (PKG activator) in TgNotch3^{WT} and TgNotch3^{R169C} mesenteric arteries.

1071 Responses were expressed as percentage of U46619-induced pre-constriction (n=4-

1072 7; Two-way ANOVA with Bonferroni post-test). (C) Reactive oxygen species (ROS)

1073 production measured by EPR in mesenteric arteries from 24-week-old TgNotch3^{WT}

1074 and TgNotch3^{R169C} mice (n=7; Student's *t* test). Results are normalized by protein

1075 content. (D) sGCβ1oxidation was also assessed in arteries from TgNotch3^{WT} and

1076 TgNotch3^{R169C} mice (pool of five different samples) by using a biotin-tagged dimedone-

1077 based probe that captures specifically sulfenylated proteins. (E) *Nox1* gene expression

1078 in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Analysis was by

1079 qPCR and gene expression was normalised to GAPDH (n=6-7; Student's *t* test). (F)

1080 H₂O₂ levels in TgNotch3^{WT} and TgNotch3^{R169C} mesenteric arteries were measured by

1081 Amplex Red (n=6-7; Student's *t* test). (G) *Catalase* and (H) *GPX1* gene expression in
1082 mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Analysis was by qPCR
1083 and gene expression was normalised to GAPDH (n=6-8; Student's *t* test). Results are
1084 expressed as mean±SEM. # p<0.05 vs. TgN3^{WT}.

1085

1086 **Figure 7. Renal dysfunction in CADASIL mice.** Renal function in in urine from
1087 TgNotch3^{WT} and TgNotch3^{R169C} mice mice was assessed by measuring urine
1088 albumin:creatinie ratio (n=9; Student's *t* test). Results are expressed as mean±SEM.
1089 # p<0.05 vs. TgN3^{WT}.

1090

1091 **Figure 8. Human CADASIL vessels exhibit increased oxidative stress and sGCβ1**
1092 **oxidation.** (A) Levels of cGMP in VSMCs from control and CADASIL patients in the
1093 presence and absence of fasudil or 4-PBA (n=5; One-way ANOVA with Dunnett post-
1094 test). Results are expressed as mean±SEM. # p<0.05 vs. TgN3^{WT}. (B) sGCβ1
1095 oxidation assessed in control and CADASIL VSMCs (pool of five different samples)
1096 using a biotin-tagged dimedone-based probe that captures specifically sulfenylated
1097 proteins. (C) Representative images from two different control and CADASIL patients
1098 and (D) analysis of 8-hydroxyguanosine (8-OHG) in brain vessels. Nuclei are in blue
1099 (DAPI) and 8-OHG in green (arrows). Scale bars = 50 μm; 20x (n=3-4; Student's *t*
1100 test). Results are expressed as mean±SEM. *** p<0.001 vs. Control.

1101

1102 **Figure 9. Schematic demonstrating putative molecular mechanisms underlying**
1103 **the peripheral vasculopathy associated with CADASIL.** In vascular smooth muscle
1104 cells, gain of function of Notch3 leads to oxidative stress and decreased activation of
1105 the eNOS/NO/cGMP pathway, processes associated with Rho kinase activation and

1106 ER stress. These signaling events promote increased vasoconstriction and reduced
1107 vasodilation, leading to impaired vascular function in CADASIL. eNOS, endothelial
1108 nitric oxide synthase; NO, nitric oxide; cGMP, cyclic GMP.